Self Collection- Saliva
Achieve Superior DNA Yields and Quality from Saliva Collection
Saliva sampling is a useful non-invasive means for offsite DNA collection. Whole saliva collection has clear advantages over other alternatives such as buccal abrasion swabs, foam swabs and oral rinse, including higher DNA yield and better DNA quality.
Make the Right Choice – Self Collection
|Properties||SalivaGard HT DNA||SalivaGard DNA|
|DNA Yield and Purity||Excellent||Excellent|
|DNA Stability-Ambient Temp||>1 year||>1 year|
|Ease of Use||Excellent||Very Good|
|Bar Code Labels||Yes||No|
|Use Case||High-throughput||Small-Mid scale studies|
The Biomatrica Advantage – Self Collection
Scalability: The robustness of SalivaGard gives global, scalable performance. Transition easily from bench to neighborhood clinic or consumer due to the protection against variances caused by shipping and temperature.
Reduce Costs: Get better user compliance with SalivaGard DNA HT for fewer re-works and greater processing flexibility.
Reliability & Supply Security: Biomatrica has been in business since 2005 and is relied upon by key organizations including: Roche, Thermo Fisher, GenMark and Kaiser Permanente.
Global Access: SalivaGard DNA HT has a CE mark and path to regulatory approval in a number of countries.
Maximal DNA Yield: SalivaGard has on average 25% greater DNA yield than Oragene with equivalent DNA purity.
NGS/WGS: These demanding applications require large amounts of DNA, and SalivaGard delivers.
HT: Transition quickly to high-throughput automation by leveraging SalivaGard DNA HT pierceable caps and triple-redundant labels that are LIMS compatible.
Fastest Protocol: SalivaGard does not require incubation in a water bath. Save at least one hour during DNA extraction.
Robustness: SalivaGard is resistant to temperature excursions resulting in fewer compromised samples during shipping in summer or high-temperate zones, and stabilizes DNA for over a year.
Hard Lessons Learned:
Impacts of Pre-Analytical Variance on Liquid Biopsy Clinical Trials
This white-paper explores how upstream assay factors impacted six clinical trials. Encompassing both regional and global teams, learn the commonalities in six trials that initially fell short and the likely responsible mechanisms.
Get the Most from Your Assay
We Can Help You:
Reduce Pre-analytical Variations
Ease Shipping & Storage Logistics
Increase User Compliance
Improve Assay Throughput